{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}],"title":"Anemia (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"comment":"CTCAE grade not defined.","groupId":"OG000","value":"NA"},{"comment":"CTCAE grade not defined.","groupId":"OG001","value":"NA"}]}],"title":"Anemia (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hemoglobin increased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"comment":"CTCAE grade not defined.","groupId":"OG000","value":"NA"},{"comment":"CTCAE grade not defined.","groupId":"OG001","value":"NA"}]}],"title":"Hemoglobin increased (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"}]}],"title":"Lymphocyte count decreased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Lymphocyte count decreased (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Lymphocyte count increased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"comment":"CTCAE grade not defined.","groupId":"OG000","value":"NA"},{"comment":"CTCAE grade not defined.","groupId":"OG001","value":"NA"}]}],"title":"Lymphocyte count increased (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"19"}]}],"title":"Neutrophil count decreased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}],"title":"Neutrophil count decreased (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Platelet count decreased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Platelet count decreased (Postbaseline Maximum Grade 4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}],"title":"White blood cell decreased (Postbaseline Maximum Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"White blood cell decreased (Postbaseline Maximum Grade 4)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"Laboratory test results were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grades 1 and 2 indicate mild and moderate AE, respectively; Grades 3 and 4 indicate severe AE and life-threatening consequences respectively; Grade 5 indicates death due to AE. Participants with laboratory test abnormalities were summarized according to the worst grade for each laboratory test result. All participants meeting the postbaseline grade criteria in the table below had baseline maximum grades lower than 3.","groups":[{"description":"Lorlatinib monotherapy at the recommended Phase 2 dose of 100 mg, was administered orally once daily (QD) at approximately the same time of the day on a continuous daily dosing schedule. Each treatment cycle was defined as 28 days. Treatment continued until confirmation of RECIST version 1.1 defined disease progression assessed by the blinded independent central review (unless clinical benefit was still achievable), participant refusal, participant lost to follow-up, unacceptable toxicity, death, or the study was terminated by the sponsor, whichever occurred first.","id":"OG000","title":"Lorlatinib"},{"description":"Crizotinib monotherapy at the registered dose of 250 mg, was administered orally twice daily (BID) at approximately the same time in the morning and evening (12 hours apart) on a continuous daily dosing schedule. Each treatment cycle was defined as 28 days. Treatment continued until confirmation of RECIST version 1.1 defined disease progression assessed by the blinded independent central review (unless clinical benefit was still achievable), participant refusal, participant lost to follow-up, unacceptable toxicity, death, or the study was terminated by the sponsor, whichever occurred first.","id":"OG001","title":"Crizotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants in the safety analysis population who had at least one on-study assessment for the parameter of interest.","reportingStatus":"POSTED","timeFrame":"From Baseline up to 33 months","title":"Number of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4","type":"SECONDARY","unitOfMeasure":"Participants"}